Testing immunotherapy with chemo after lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding an immunotherapy medicine to standard chemotherapy after surgery can improve outcomes for some people with non-small cell lung cancer. It may help by boosting the immune system to reduce the chance the cancer comes back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 18 years old, and you can do study visits well (ECOG 0–1).
- Your lung cancer was fully removed by surgery with no cancer left at the edges (R0 resection).
- You have the right tumor test results: no EGFR exon 19 deletion or EGFR L858R, and no ALK rearrangement (this applies to non-squamous lung cancer).
- Your tumor has been tested for PD-L1 using an approved lab test method.
- You haven’t had chemo or immunotherapy (neoadjuvant or adjuvant) for this lung cancer before.
- You meet key safety checks (no serious uncontrolled illness, no past non-infectious steroid-requiring lung inflammation, and blood/organ tests in range).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy (durvalumab) after surgery can help prevent lung cancer from coming back if you already had a complete response to chemo and immunotherapy before surgery. It is for people with early-stage non-small cell lung cancer who had no cancer left after treatment.
This trial tests whether giving chemotherapy plus immunotherapy before surgery helps people with a specific type of advanced lung cancer. It aims to see if this approach can shrink tumors and make surgery more effective.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests whether giving an immune-boosting drug (Tα1) along with chemotherapy and immunotherapy before surgery helps people with stage II-IIIB non-small cell lung cancer that can be removed. It aims to see if this combination makes the cancer shrink more and improves outcomes.
This trial combines surgery to remove the main lung tumor with chemo and an immunotherapy drug called sintilimab. It's for people with advanced non-small cell lung cancer that hasn't been treated before and doesn't have certain gene changes.
This trial tests if receiving immunotherapy before surgery works better than getting it after surgery for people with stage II to IIIB non-small cell lung cancer. The goal is to see which timing helps prevent the cancer from coming back.
Hear when a new Lung Non-Squamous Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.